The impact of out-of-pocket payments on prevention and health-related lifestyle: A systematic literature review

European Journal of Public Health

Volumn 23, Issue 1, 2013, Pages 74-79

  Rezayatmand, Reza ^a,b   Pavlova, Milena ^a   Groot, Wim ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATTITUDE TO HEALTH; COST; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LIFESTYLE; PREVENTIVE HEALTH SERVICE; REVIEW; SECONDARY PREVENTION; STATISTICS; UTILIZATION REVIEW;

ATTITUDE TO HEALTH; COST SHARING; FINANCING, PERSONAL; HEALTH BEHAVIOR; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH; LIFE STYLE; PREVENTIVE HEALTH SERVICES; SECONDARY PREVENTION;

MLCS; MLOWN;

EID: 84876561172     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/cks034     Document Type: Article

References (38)

1. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Managed Care 2001;7:861-74.
2. Courbage C, Coulon Ad. Prevention and private health insurance in the UK. Geneva Pap Risk Ins 2004;29:719-27.
3. Barigozzi F. Reimbursing preventive care. Geneva Pap Risk Ins 2004;29:165-86.
4. Kenkel D. Prevention. In: Culyer A, Newhouse J, editors. Handbook of health economics. North-Holland: Elsevier, 2000: 1676-720.
5. Thomson S, Mossialos E, Jemiai N. Cost sharing for health services in the European Union. Report prepared for the European Commission Directorate General for Employment and Social Affairs. London, London School of Economics and Political Science, 2003.
6. Krist AH, Woolf SH, Johnson RE, et al. Patient costs as a barrier to intensive health behavior counseling. Am J Prev Med 2010;38:344-8.
7. Fronstin P. Findings from the 2009 EBRI/MGA Consumer Engagement in Health Care Survey. EBRI 2009;337:1-42.
8. Schneider U, Zerth J. Improving prevention compliance through appropriate incentives: theoretical modelling and empirical evidence. SJES 2011;147:71-106.
9. Boyle RG, Solberg LI, Magnan S, et al. Does insurance coverage for drug therapy affect smoking cessation Health Aff 2002;21:162-8.
10. Cherkin D, Grothaus L, Wagner E. The effect of office visit copayments on preventive care services in an HMO. Inquiry: a journal of medical care organization, provision and financing 1990;27:24-38.
11. Lurie N, Manning WG, Peterson C, et al. Preventive care: do we practice what we preach? Am J Pub Health 1987;77:801-4.
12. Ashraf N, Berry J, Shapiro JM.Can higher prices stimulate product use? Evidence from a field experiment in Zambia. The National Bureau of Economic Research. Cambridge, MA, USA; 2007. Working paper No. 13247.
13. Harvey PD. The impact of condom prices on sales in social marketing programs. Stud Family Planning 1994;25:52-8.
14. Pilote L, Beck C, Richard H, Eisenberg MJ. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. Can Med Ass J 2002;167:246-52.
15. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care 1997;35:1119-31.
16. Solanki G, Schauffler HH. Cost-sharing and the utilization of clinical preventive services. Am J Prev Med 1999;17:127-33.
17. Solanki G, Schauffler HH, Miller LS. The direct and indirect effects of cost-sharing on the use of preventive services. Health Serv Res 2000;34:1331-50.
18. Faulkner LA, Schauffler HH. The effect of health insurance coverage on the appropriate use of recommended clinical preventive services. Am J Prev Med 1997;13:453-8.
19. Reinhardt UE. Reforming the health care system: the universal dilemma. Am J L Med 1993;19:21-36.
20. Ros CC, Groenewegen PP, Delnoij DMJ. All rights reserved, or can we just copy? Cost sharing arrangements and characteristics of health care systems. Health Policy 2000;52:1-13.
21. Burke JP, Sander S, Shah H, et al. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. Curr Med Res Opin 2010;26:1023-30.
22. Skriabikova O, Pavlova M, Groot W. Empirical models of demand for out-patient physician services and their relevance to the assessment of patient payment policies: a critical review of the literature. Int J Environ Res Pub Health 2010;7:2708-25.
23. Choudhry NK, Avorn J, Antman EM, et al. Should patients receive secondary prevention medications for free after a myocardial infarction An economic analysis. Health Aff 2007;26:186-94.
24. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Managed Care 2006;12:678-83.
25. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Eng J Med 2003;349:2224-32.
26. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-45.
27. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 2005;11(5 suppl):S170-6.
28. Landsman PB, YU W, Liu X, et al. Imapact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Managed Care 2005;11:621-8.
29. Piette JD, Wagner TH, Potter MB, Schillinger D. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004;42:102-9.
30. Blustein J. Drug coverage and drug purchases by Medicare beneficiaries with hypertension. Health Affairs 2000;19:219-30.
31. Cohen J, Dupas P.Free distribution or cost-sharing? Evidence from a malaria prevention experiment. The National Bureau of Economic Research. Cambridge, MA, USA; 2008. Working paper No. 14406.
32. Okrah J, Traoré C, Palé A, Sommerfeld J, Muller O. Community factors associated with malaria prevention by mosquito nets: an exploratory study in rural Burkina Faso. Trop Med Int Health 2002;7:240-8.
33. Guyatt HL, Ochola SA, Snow RW. Too poor to pay: charging for insecticide treated bednets in highland Kenya. Trop Med Int Health 2002;7:846-50.
34. Brinkhof MWG, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull WHO 2008;86:559-67.
35. Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care 2004;42:626-34.
36. Lemmens V, Oenema A, Knut IK, Brug J. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. Eur J Cancer Prev 2008;17:535.
37. Jones AM. Health, addiction, social interaction and the decision to quit smoking. J Health Econ 1994;13:93-110.
38. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff 2008;27:103-12.